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CORRESPONDENCE
Isolation in France of a clinical strain of Streptococcus
pneumoniae susceptible to amoxycillin and resistant to
cefotaxime
Resistance of Streptococcus pneumoniae to b-lactam antibiotics
is due to the low affinity of its penicillin-binding proteins
(PBPs) for these molecules. Alterations of PBP1a, PBP2x and
PBP2b lead to a decrease in the activity of most b-lactams,
including penicillin G, amoxycillin and third-generation
cephalosporins [1].
Usually, the minimal inhibitory concentrations (MICs) of
cefotaxime and ceftriaxone against penicillin-resistant pneu-
mococci (PRP) remain lower than those of penicillin G and
amoxycillin by one or two dilutions; these third-generation
cephalosporins have thus been proposed as alternative drugs
for the treatment of severe infections due to PRP, such as
meningitis [2].
In the USA and recently in Spain, some infections due to
PRP with cefotaxime MICs exceeding those of penicillin G
have been reported that did not respond to third-generation
cephalosporin therapy [3,4]. The North American isolates
were of serotype 23F or 6B, and their PBP patterns, ribotypes
and pulsed-field gel electrophoresis profiles appeared to be
closely related [5].
To the best of our knowledge, pneumococcal strains more
resistant to cefotaxime and ceftriaxone than to amoxycillin and
penicillin G have not previously been isolated in France.
We report the isolation of a PRP strain resistant to cefotaxime
but susceptible to amoxycillin in a patient suffering from a
community-acquired pneumonia.
In January 1997, a 75-year-old man receiving prednisone
7.5 mg daily for pulmonary emphysema evolving for 15 years
was admitted to our hospital. He presented with a 2-week
history of respiratory tract infection treated with amoxycillin–
clavulanate 1 g daily for 5 days; 5 days after the end of antibiotic
therapy, there was exacerbation of cough and recurrence of
fever. He presented with a productive cough, thoracic pain
and fever (40 °C). The physical examination noted tachycardia
(100/min), dyspnea (40/min) and cyanosis. X-ray revealed a
left chest infiltrate, and the white blood cell count was
23.4  109/L (90% neutrophils). Bronchoaspiration was per-
formed. The patient received intravenous cefotaxime 2 g and
erythromycin 3 g daily for 8 days, and then cefotaxime alone
for 5 days. The outcome was rapidly favorable and he was
discharged after 15 days.
Serologic results revealed only the presence of Chlamydia-
specific IgG, IgM and IgA antibodies by an ELISA technique.
The bronchoaspiration fluid was not purulent but the culture
produced a S. pneumoniae strain (107 CFU/mL), serotype 14,
which was screened as penicillin resistant by the oxacillin disk
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test. The strain was resistant to erythromycin (MIC 
128 mg/L), but susceptible to co-trimoxazole, doxycycline and
rifampin. MICs of b-lactams were determined by using the
NCCLS reference microbroth dilution method [6], the agar
dilution method and the E test method. Depending on the
method used, the MICs of penicillin G and amoxycillin varied
from 0.38 to 0.5 mg/L and from 0.064 mg/L to 0.125 mg/L,
respectively. Therefore, the strain was classified as displaying
diminished susceptibility to penicillin and as being susceptible
to amoxycillin [7]. In contrast, the MICs of cefotaxime and
ceftriaxone were 4 mg/L irrespective of the method used, cat-
egorizing the strain as resistant. Identification and MICs were
confirmed by the Centre National de Re´fe´rence du Pneumo-
coque (Dr Geslin, Cre´teil, France).
The clinical significance of resistance to cefotaxime in this
report remains unclear, since the etiology of the infection
could not be definitely attributed to S. pneumoniae. The role of
an intracellular pathogen, in particular Chlamydia pneumoniae,
could not be ruled out. However, one should be aware that
amoxycillin-susceptible and cefotaxime-resistant S. pneumo-
niae can now be isolated in Europe and that susceptibility to
cefotaxime cannot be inferred from susceptibility to amoxy-
cillin. In every case of severe infection, the MIC of the b-
lactam used in the treatment of a patient should be determined.
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Subacute polyradiculoneuritis revealing syphilis in an HIV-negative
man
Although the incidence of neurosyphilis has dramatically
decreased since the introduction of antibiotics, it is still preva-
lent, particularly in the HIV-infected population [1]. Its most
common clinical presentation includes tabes dorsalis and general
paresis [2,3]. In contrast, polyradiculoneuritis has seldom been
reported during syphilis [4–6]. We thus report a case of subacute
polyradiculoneuritis caused by Treponema pallidum in an HIV-
negative man and review the other cases.
A Niger-native 40-year-old man presented in June 1991
with pain in the legs, which suddenly disappeared. In December
1991, leg weakness and heaviness reappeared, creating walking
difficulties. In January 1992, he suddenly presented a tetra-
paresia with absence of deep tendon reflexes but no sensory
deficit, which justified his admission at the hospital in Niamey
(Niger). Three weeks later, he was referred to Paris (France) in
order for the investigations to be completed. Physical exam-
ination revealed good general condition, apyrexia and no extra-
neurologic signs. There was a discrete bilateral muscular leg
weakness predominating proximally. Deep tendon reflexes
were reduced at the knees and absent at the ankles. There
were no pyramidal signs and no incontinence. Sphincter tone,
vibration, joint position and pinprick sensation were normal.
However, there was a cutaneous hyperesthesia on the legs.
There was a bilateral Argyll Robertson’s sign. Cerebrospinal
fluid (CSF) examination showed less than 1 cell/mL, protein
level 1.1 g/L with normal glucose, and increased gamma-
globulin (IgG = 228 mg/L, normal 7–61 mg/L) levels. The
Venereal Disease Research Laboratory (VDRL) test was nega-
tive in the CSF, but CSF T. pallidum hemagglutination assay
(TPHA) was positive (1/80) in the CSF, and TPHA index
(TPHA CSF/serum  1000  albumin serum/CSF) was
793. Serum VDRL was reactive in a 1 : 32 dilution, serum
TPHA in a 1 : 640 dilution, and serum FTA-abs in a 1 : 25 600
dilution. The search for HIV-1 and HIV-2 antibodies was
negative in the serum.
The patient received 25 million units of intravenous aqueous
crystalline penicillin G daily for 3 weeks. Muscular leg weakness
disappeared and his clinical condition dramatically improved.
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